The US FDA for the third time has refused to give approval to Lipocine’s oral testosterone drug, Tlando. The drug is an oral testosterone replacement therapy in clinical trials for the treatment of Primary and Secondary hypogonadism in males. The drug contains containing Testosterone Undecanoate (TU) which helps in restoring normal levels of testosterone. This … Continue reading FDA declines the approval of Lipocine’s testosterone drug; Novartis Sandoz to buy Aspen Pharmacare Japanese Unit